PHARMACEUTICAL COMPOSITION CONTAINING 1-DIPHENYLMETHYL-4-((2-(4-METHYLPHENYL)-5-METHYL-1H-IMIDAZOL-4-YL)METHYL)-PIPERAZINE

PHARMACEUTICAL COMPOSITION CONTAINING 1-DIPHENYLMETHYL-4-((2-(4-METHYLPHENYL)-5-METHYL-1H-IMIDAZOL-4-YL)METHYL)-PIPERAZINE

A pharmaceutical formulation suitable for parenteral (preferably intravenous) administration includes an effective amount of 1-diphenylmethyl-4-[(2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)meth yl]piperaz ine and a suitable amount of an acid to generate a pharmaceutically acceptable salt having a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SELKIRK, ALASTAIR BRERETON, DEY, MICHAEL JOHN
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A pharmaceutical formulation suitable for parenteral (preferably intravenous) administration includes an effective amount of 1-diphenylmethyl-4-[(2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)meth yl]piperaz ine and a suitable amount of an acid to generate a pharmaceutically acceptable salt having a pH above about 3.0 and a solubility above about 4.0 mg/ml. The intravenous formulation optionally includes a suitable tonicifier in a quantity sufficient to achieve isotonicity with body fluids. The salt is formed in situ during the formulation process. The salt of tartaric acid is preferred; suitable salts for lower concentration dosages are the citric acid and methane sulphonic acid salts.